Insulin Resistance and Gynecologic Disease – References

Andréa C. Salcedo

Current: Board Certified Obstetrician and Gynecologist; Assistant Professor of Gynecology and Obstetrics

Past: Private Practice, Conscious Gynecology, Claremont, CA; Loma Linda University School of Medicine, Loma Linda, CA

Dr. Andrea Salcedo, an Obstetrics and Gynecology surgeon and clinical researcher at Loma Linda University, advances women’s health by investigating

Learn more
References

Insulin Resistance and Gynecologic Disease – References

  1. Cardozo ER, Clark AD, Banks NK, Henne MB, Stegmann BJ, Segars JH. The estimated annual cost of uterine leiomyomata in the United States. Am J Obstet Gynecol. 2012;206(3):211.e1-211.e9. doi:10.1016/j.ajog.2011.12.002 
  2. Flynn M, Jamison M, Datta S, Myers E. Health care resource use for uterine fibroid tumors in the United States. Am J Obstet Gynecol. 2006;195(4):955-964. doi:10.1016/j.ajog.2006.02.020 
  3. Matteson KA, Raker CA, Clark MA, Frick KD. Abnormal uterine bleeding, health status, and usual source of medical care: analyses using the Medical Expenditures Panel Survey. J Womens Health 2002. 2013;22(11):959-965. doi:10.1089/jwh.2013.4288
  4. Silver MA, Raghuvir R, Fedirko B, Elser D. Systemic hypertension among women with uterine leiomyomata: potential final common pathways of target end-organ remodeling. J Clin Hypertens Greenwich Conn. 2005;7(11):664-668. doi:10.1111/j.1524-6175.2005.04384.x 
  5. Boynton-Jarrett R. A Prospective Study of Hypertension and Risk of Uterine Leiomyomata. Am J Epidemiol. 2005;161(7):628-638. doi:10.1093/aje/kwi072
  6. Uimari O, Auvinen J, Jokelainen J, et al. Uterine fibroids and cardiovascular risk. Hum Reprod. 2016;31(12):2689-2703. doi:10.1093/humrep/dew249
  7. Nappi L, Indraccolo U, Sardo ADS, et al. Are Diabetes, Hypertension, and Obesity Independent Risk Factors for Endometrial Polyps? J Minim Invasive Gynecol. 2009;16(2):157-162. doi:10.1016/j.jmig.2008.11.004 
  8. Scicchitano P, Dentamaro I, Carbonara R, et al. Cardiovascular Risk in Women With PCOS. Int J Endocrinol Metab. 2012;10(4):611-618. doi:10.5812/ijem.4020
  9. Marchandot B, Curtiaud A, Matsushita K, et al. Endometriosis and cardiovascular disease. Bäck M, ed. Eur Heart J Open. 2022;2(1):oeac001. doi:10.1093/ehjopen/oeac001
  10. Moss NS, Benditt EP. Human atherosclerotic plaque cells and leiomyoma cells. Comparison of in vitro growth characteristics. Am J Pathol. 1975;78(2):175-190.
  11. Mesquita FS, Dyer SN, Heinrich DA, Bulun SE, Marsh EE, Nowak RA. Reactive oxygen species mediate mitogenic growth factor signaling pathways in human leiomyoma smooth muscle cells. Biol Reprod. 2010;82(2):341-351. doi:10.1095/biolreprod.108.075887
  12. Nijkang NP, Anderson L, Markham R, Manconi F. Endometrial polyps: Pathogenesis, sequelae and treatment. SAGE Open Med. 2019;7:205031211984824. doi:10.1177/2050312119848247
  13. Çınar M, Eryılmaz ÖG, Özel Ş, Fındık RB, Kansu H, Özakşit G. The role of oxidative stress markers in development of endometrial polyp. J Exp Ther Oncol. 2016;11(4):269-273.
  14. Salcedo A, Fox L, de los Santos G, Larson S, Yun J. The Uterus is an End Organ: a preliminary study of the association between abnormal uterine bleeding & hyperinsulinemia. Menopause. Published online August 2025.
  15. Salcedo AC, Yun J, Carter C, Hart E. Therapeutic Carbohydrate Restriction as a Metabolic Modality for the Prevention and Treatment of Abnormal Uterine Bleeding. Nutrients. 2023;15(17):3760. doi:10.3390/nu15173760
  16. Creanga AA, Catalano PM, Bateman BT. Obesity in Pregnancy. Longo DL, ed. N Engl J Med. 2022;387(3):248-259. doi:10.1056/NEJMra1801040
  17. Catalano PM. Obesity, insulin resistance, and pregnancy outcome. REPRODUCTION. 2010;140(3):365-371. doi:10.1530/REP-10-0088
  18. Huda SS, Brodie LE, Sattar N. Obesity in pregnancy: prevalence and metabolic consequences. Semin Fetal Neonatal Med. 2010;15(2):70-76. doi:10.1016/j.siny.2009.09.006
  19. Opichka MA, Rappelt MW, Gutterman DD, Grobe JL, McIntosh JJ. Vascular Dysfunction in Preeclampsia. Cells. 2021;10(11):3055. doi:10.3390/cells10113055
  20. Kampmann U, Knorr S, Fuglsang J, Ovesen P. Determinants of Maternal Insulin Resistance during Pregnancy: An Updated Overview. J Diabetes Res. 2019;2019:1-9. doi:10.1155/2019/5320156
  21. Main EK, McCain CL, Morton CH, Holtby S, Lawton ES. Pregnancy-Related Mortality in California: Causes, Characteristics, and Improvement Opportunities. Obstet Gynecol. 2015;125(4):938-947. doi:10.1097/AOG.0000000000000746 
  22. Harvey SV, Pfeiffer RM, Landy R, Wentzensen N, Clarke MA. Trends and predictors of hysterectomy prevalence among women in the United States. Am J Obstet Gynecol. 2022;227(4):611.e1-611.e12. doi:10.1016/j.ajog.2022.06.028
  23. Hoeger KM, Dokras A, Piltonen T. Update on PCOS: Consequences, Challenges, and Guiding Treatment. J Clin Endocrinol Metab. 2021;106(3):e1071-e1083. doi:10.1210/clinem/dgaa839
  24. Jacewicz-Święcka M, Kowalska I. Changes in Metabolic Profile in the Women with a History of PCOS—A Long-Term Follow-Up Study. J Clin Med. 2020;9(10):3367. doi:10.3390/jcm9103367
  25. Wang ET, Calderon-Margalit R, Cedars MI, et al. Polycystic Ovary Syndrome and Risk for Long-Term Diabetes and Dyslipidemia. Obstet Gynecol. 2011;117(1):6-13. doi:10.1097/AOG.0b013e31820209bb
  26. Salcedo AC, Shehata H, Berry A, Riba C. Insulin resistance and other risk factors of cardiovascular disease amongst women with abnormal uterine bleeding. J Insul Resist. 2022;5(1). doi:10.4102/jir.v5i1.67
  27. Camajani E, Feraco A, Verde L, et al. Ketogenic Diet as a Possible Non-pharmacological Therapy in Main Endocrine Diseases of the Female Reproductive System: A Practical Guide for Nutritionists. Curr Obes Rep. Published online July 5, 2023. doi:10.1007/s13679-023-00516-1
  28. Gershuni VM, Yan SL, Medici V. Nutritional Ketosis for Weight Management and Reversal of Metabolic Syndrome. Curr Nutr Rep. 2018;7(3):97-106. doi:10.1007/s13668-018-0235-0
  29. Li J, Bai W, Jiang B, et al. Ketogenic diet in women with polycystic ovary syndrome and liver dysfunction who are obese: A randomized, open‐label, parallel‐group, controlled pilot trial. J Obstet Gynaecol Res. 2021;47(3):1145-1152. doi:10.1111/jog.14650
  30. Palafox-Gómez C, Ortiz G, Madrazo I, López-Bayghen E. Adding a ketogenic dietary intervention to IVF treatment in patients with polycystic ovary syndrome improves implantation and pregnancy. Reprod Toxicol. 2023;119:108420. doi:10.1016/j.reprotox.2023.108420
  31. Anderson G. Endometriosis Pathoetiology and Pathophysiology: Roles of Vitamin A, Estrogen, Immunity, Adipocytes, Gut Microbiome and Melatonergic Pathway on Mitochondria Regulation. Biomol Concepts. 2019;10(1):133-149. doi:10.1515/bmc-2019-0017
  32. Liu Z, Chen P, Luo L, Liu Q, Shi H, Yang X. Causal effects of gut microbiome on endometriosis: a two-sample mendelian randomization study. BMC Womens Health. 2023;23(1):637. doi:10.1186/s12905-023-02742-0
  33. Lobionda S, Sittipo P, Kwon HY, Lee YK. The Role of Gut Microbiota in Intestinal Inflammation with Respect to Diet and Extrinsic Stressors. Microorganisms. 2019;7(8):271. doi:10.3390/microorganisms7080271
  34. Abokhrais IM, Denison FC, Whitaker LHR, et al. A two-arm parallel double-blind randomised controlled pilot trial of the efficacy of Omega-3 polyunsaturated fatty acids for the treatment of women with endometriosis-associated pain (PurFECT1). Rozenberg P, ed. PLOS ONE. 2020;15(1):e0227695. doi:10.1371/journal.pone.0227695
  35. Nodler JL, DiVasta AD, Vitonis AF, et al. Supplementation with vitamin D or ω-3 fatty acids in adolescent girls and young women with endometriosis (SAGE): a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr. 2020;112(1):229-236. doi:10.1093/ajcn/nqaa096.

Related topics